Na Febụwarị 7, 2025, Sichuan Kelun-Biotech Biopharmaceutical kwupụtara nkwenye nke Cetuximab N01 Injection site na National Medical Products Administration maka ọgwụgwọ nke kansa eriri afọ metastatic (mCRC) na China.
Nkwenye a dabere na nnukwu nnyocha ahụike nke ọkwa nke atọ nke na-egosi nha anya ọgwụ ahụ na arụmọrụ na nchekwa ya na ọgwụgwọ ndị dị ugbu a, nke nwere ike ịbawanye ohere ọgwụgwọ maka mCRC na China ebe ọnụọgụ ọnwụ na-arị elu.
Nnyocha ahụ gụnyere ngụkọta nke ndị ọrịa 688, nsonaazụ ya gosikwara na usoro ọgwụgwọ chemotherapy nke cetuximab N01 kwekọrọ na ọnụego nzaghachi ebumnuche (ORR) ma e jiri ya tụnyere ọgwụ chemotherapy nke cetuximab (Erbitux) jikọtara ọnụ (ORR). Ọnụego nzaghachi ebumnuche (ORR) nke ọgwụ cetuximab N01 na ọgwụ cetuximab (Erbitux) bụ 71.0% na 77.5%, n'otu n'otu. Enweghị ọdịiche dị mkpa na ahụike ma ọ bụ n'ọnụọgụgụ na oge nzaghachi (DoR) na ndụ enweghị ọganihu (PFS) n'etiti ọgwụ cetuximab N01 na ọgwụ cetuximab (Erbitux), yana ndụ enweghị ọganihu nke ọnwa 10.9 na ọnwa 10.8, n'otu n'otu.
N'ihe gbasara nchekwa, nnwale ahụike nke a na-achịkwa nkebi nke atọ nke isi ruo n'isi na-egosi nke ọma na usoro ọgwụgwọ chemotherapy nke cetuximab N01 yiri nke a ma e jiri ya tụnyere ọgwụ chemotherapy a na-agbakọta na cetuximab (Erbitux).
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Email：myimmnet@163.com
Ntụaka
1.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250207150842162.html
2.Wu CC, Hsu CW, Hsieh MC, na ndị ọzọ. Usoro Kachasị Mma na Ọgwụgwọ Sistemụ nke Abụọ nke Ndị Ọrịa Nwere Ọrịa Kansa Anụ ọhịa nke RAS: Nyocha Meta-Analysis. J Clin Med. 2021 Nọvemba 4;10(21):5166.
Oge ozi: Febụwarị-13-2025